Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice
Authors:
- J.B VermorkenJVJ.B Vermorken
- G.J PetersG.J Peters
- 1 May 1999
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 35 (5) , 808-814
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell linesBritish Journal of Cancer, 1999
- United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)British Journal of Cancer, 1998
- Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumorsCancer Chemotherapy and Pharmacology, 1996
- Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumoursBritish Journal of Cancer, 1996
- Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenograftsEuropean Journal of Cancer, 1995
- 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell linesBiochemical Pharmacology, 1993
- Platinum—DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometryCarcinogenesis, 1991
- The coordination chemistry of platinum anticancer drugs and related compounds with DNACoordination Chemistry Reviews, 1990
- Determination of subcutaneous tumor size in athymic (nude) miceCancer Chemotherapy and Pharmacology, 1989
- Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosidesThe Journal of Organic Chemistry, 1988